Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Shares Outstanding for 5 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 25.61% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 25.61% increase, with the full-year FY2024 number at $65.5 million, up 5625.42% from a year prior.
  • Shares Outstanding was $1.6 million for Q3 2025 at Lyra Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $49.5 million in Q3 2023 to a low of $1.1 million in Q4 2023.
  • A 5-year average of $15.9 million and a median of $13.0 million in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: surged 144.8% in 2022, then plummeted 97.84% in 2025.
  • Lyra Therapeutics' Shares Outstanding stood at $13.0 million in 2021, then skyrocketed by 144.69% to $31.8 million in 2022, then crashed by 96.4% to $1.1 million in 2023, then rose by 14.51% to $1.3 million in 2024, then rose by 25.5% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Shares Outstanding are $1.6 million (Q3 2025), $1.6 million (Q2 2025), and $1.3 million (Q1 2025).